Introduction: Who Should Seek Diagnostic Testing for MELAS Syndrome

Recognizing when to pursue diagnostic testing for MELAS syndrome is an important first step in managing this condition. Individuals who should consider undergoing diagnostic evaluation include those who experience repeated episodes resembling strokes, particularly if these occur before the age of 40, along with other symptoms like seizures, severe headaches similar to migraines, or muscle weakness.^[1] Nearly three-quarters of MELAS cases are identified before the age of 20, though symptoms can appear as early as before age 2 or as late as after age 40.^[5]

It is especially important to seek diagnostic testing if there is a family history of the condition. Because MELAS is inherited through the mother’s side of the family, anyone whose mother has been diagnosed with MELAS, or who has family members with similar unexplained neurological symptoms, should discuss screening with their healthcare provider.^[1] Almost all people with MELAS develop diabetes and hearing loss before experiencing brain-related symptoms, so the presence of these two conditions together in a young person should prompt further investigation.^[1]

Children who show signs of normal early development followed by sudden onset of neurological problems between ages 2 and 15 warrant careful evaluation. These problems might include recurrent vomiting, extreme fatigue, short stature, behavioral changes, confusion, or difficulty with movement and coordination.^[2] Parents should not dismiss these symptoms as simply part of childhood illness, particularly when they occur in patterns or episodes.

Classic Diagnostic Methods for MELAS Syndrome

Diagnosing MELAS syndrome begins with a thorough medical history and physical examination. Your healthcare provider will ask detailed questions about your symptoms, when they began, how often they occur, and whether anyone in your family has similar health problems. They will pay particular attention to symptoms affecting the brain, nervous system, and muscles, as well as the presence of diabetes or hearing problems.^[1]

Once the provider suspects MELAS or another mitochondrial disorder, they will recommend several types of testing. Genetic testing is the only way to definitively confirm MELAS syndrome.^[5] This involves analyzing your DNA to look for specific changes, or mutations, in mitochondrial genes. Around 80% of people with MELAS have a particular genetic change called the m.3243A>G mutation in the MT-TL1 gene.^[2] However, testing may need to examine multiple genes because MELAS can be caused by variations in at least 17 different mitochondrial genes.^[8]

Blood testing plays an important role in the diagnostic process. Laboratory tests can measure the level of lactic acid, a substance that builds up in the blood when mitochondria are not working properly. Increased lactic acid in the blood is a hallmark feature of MELAS syndrome and can provide important clues about the presence of mitochondrial dysfunction.^[3] Blood samples may also be tested for levels of an enzyme called creatine kinase, which can be elevated in people with muscle disorders.^[3] These metabolic markers, while helpful, are not specific to MELAS alone, so they must be interpreted alongside other test results.^[20]

Tests of cerebrospinal fluid, the liquid that surrounds the brain and spinal cord, may also be performed. This test is called a lumbar puncture or spinal tap. Measuring lactic acid levels in cerebrospinal fluid can be more informative than blood tests in some cases because it directly reflects what is happening in the nervous system.^[3] Additionally, urine samples can be useful, particularly for detecting the 3243A>G mutation, which is often present at higher levels in urine than in blood, making it easier to identify.^[20]

Imaging tests are essential for understanding how MELAS affects the brain. Magnetic resonance imaging, or MRI, is the most commonly used imaging technique. An MRI scan uses powerful magnets and radio waves to create detailed pictures of the brain’s structure. In people with MELAS, MRI scans can reveal areas of damage that look similar to stroke damage, even though they are caused by different mechanisms.^[1] Computed tomography, or CT scans, may also be used and can show characteristic changes such as calcifications in certain areas of the brain.^[3]

A muscle biopsy is sometimes necessary when other tests do not provide clear answers. During this procedure, a small sample of muscle tissue is removed, usually from the thigh or upper arm, using a needle. The tissue is then examined under a microscope and tested for mitochondrial enzyme function and DNA mutations.^[1] If MELAS is present, the muscle tissue often shows a distinctive pattern called “ragged red fibers” when stained with certain dyes. These ragged red fibers are muscle cells that contain abnormal accumulations of defective mitochondria.^[5] The biopsy can also reveal deficiencies in specific mitochondrial enzymes responsible for energy production.^[7]

Distinguishing MELAS from other conditions is an important part of the diagnostic process. Several diseases share similar features with MELAS and must be ruled out. Kearns-Sayre syndrome, another mitochondrial disease, can present similarly with muscle problems and neurological symptoms.^[6] MERRF, which stands for myoclonus epilepsy associated with ragged red fibers, also involves seizures, mental deterioration, and muscle abnormalities. However, MERRF typically features a characteristic type of seizure called myoclonic seizures that helps distinguish it from MELAS.^[6] Leigh syndrome may present with progressive neurological problems, seizures, and vomiting, mainly in young children, making genetic testing essential to distinguish between these conditions.^[6]

Diagnostic Testing for Clinical Trial Enrollment

When individuals with MELAS syndrome consider participating in clinical trials, they typically need to undergo additional diagnostic assessments beyond those used for initial diagnosis. These tests help researchers determine whether a person meets the specific criteria for enrollment in a particular study and provide baseline measurements to track how well a treatment works during the trial.

Clinical trials usually require comprehensive documentation of the genetic mutation causing MELAS. This means participants must have molecular genetic testing that clearly identifies the specific DNA change responsible for their condition.^[3] Researchers need to know exactly which gene is affected because different mutations may respond differently to experimental treatments. Blood samples are typically used for this testing, though in some cases, testing of other tissues may be required to detect low-level mutations.

Baseline measurements of lactic acid levels in both blood and cerebrospinal fluid are commonly required for clinical trial qualification. These measurements help establish how severely the mitochondrial dysfunction is affecting the body’s metabolism before any treatment begins.^[3] Serial measurements taken throughout the trial can then show whether an experimental therapy is improving mitochondrial function.

Brain imaging is another standard requirement for clinical trial participation. Detailed MRI scans document the extent and location of brain changes at the start of the study.^[3] Follow-up scans performed during and after treatment can reveal whether a therapy prevents further brain damage or even promotes healing. Some studies may also use advanced imaging techniques like proton magnetic resonance spectroscopy, which measures chemical compounds in the brain and can detect metabolic abnormalities specific to mitochondrial disease.^[7]

Muscle biopsy results showing the presence of ragged red fibers and measurements of mitochondrial enzyme activity are often part of the enrollment criteria. These tests confirm that the mitochondria in muscle tissue are indeed dysfunctional and provide quantitative measures of how badly they are affected.^[3] Some clinical trials may repeat muscle biopsies during the study to see if experimental treatments improve mitochondrial structure or function at the cellular level.

Assessment of disease severity and functional status is crucial for clinical trial design. Researchers need to understand how MELAS is affecting each person’s daily life before treatment begins. This might include neurological examinations to document muscle strength, coordination, and mental function, as well as assessments of vision, hearing, and cardiac function.^[7] Questionnaires about quality of life, ability to perform daily activities, and frequency of stroke-like episodes provide additional baseline information.

Because patient registries like mitoSHARE are actively recruiting MELAS families to participate in research, joining such registries can be a first step toward clinical trial participation.^[3] These registries collect comprehensive health information and may conduct their own standardized diagnostic assessments, making it easier for researchers to identify suitable candidates for clinical trials. Being part of a registry also means you will be notified when new trials become available that match your specific situation.